MARKET

ORKA

ORKA

Oruka Therapeutics Inc
NASDAQ
109.50
+4.94
+4.72%
Pre Market: 114.50 +5 +4.57% 04:40 11/11 EST
OPEN
104.02
PREV CLOSE
104.56
HIGH
113.24
LOW
102.78
VOLUME
10
TURNOVER
0
52 WEEK HIGH
115.52
52 WEEK LOW
25.23
MARKET CAP
7.25B
P/E (TTM)
-44.2979
1D
5D
1M
3M
1Y
5Y
1D
Oruka Therapeutics Faces Patent Expiry Risk That Could Accelerate Generic Competition and Pressure Future Revenues
TipRanks · 4h ago
Oruka Therapeutics reports Q3 EPS (63c), consensus (62c)
TipRanks · 16h ago
Oruka's December Readout Will Test Whether Psoriasis Data Justify the Burn Rate
Barchart · 18h ago
Oruka Expects ORKA-001 52-Week Data In December; Phase 3 Start Planned For 2027
NASDAQ · 20h ago
Oruka Therapeutics (ORKA) Receives a Buy from UBS
TipRanks · 20h ago
Piper Sandler Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)
TipRanks · 21h ago
Stifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
TipRanks · 22h ago
BTIG Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
TipRanks · 23h ago
More
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Webull offers Oruka Therapeutics Inc stock information, including NASDAQ: ORKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORKA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORKA stock methods without spending real money on the virtual paper trading platform.